Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
13 October 2016
Header
Header image
From our blog

From our blog

Flexibility and Collaboration Key to Boosting Access to Life-Saving Oncology Products
13 October 2016 by Thomas Allvin

It comes as no surprise that cancer prevalence in Europe is on the rise. Across the continent, the leap from 2.6 to 3.4 million cases from 1995 to 2012 is equivalent to a staggering 31% increase. What’s more, were current trends to continue, cancer would become the leading cause of disability in Europe.

Read more

From our blog

What is outcomes-driven, sustainable healthcare and why does it matter? (Guest blog)
13 October 2016 by Christina Åkerman, Jason Arora (ICHOM)

We know what the ideal healthcare system should look like

Imagine a healthcare system in which the patient is the most empowered member of the care team.

Healthcare delivery is seamless, efficient and user-friendly for both patients and clinicians, and every component of the system contributes directly to a single goal: the outcomes that matter most to the patient. Medical practice is data-driven and technologically sophisticated, enabling a continuous self-sustaining flow of evidence-based, translational innovation and improvement; the system is dynamic and continuously able to learn from itself.

Read more

Events calendar

Events Calendar

EFPIA Health Collaboration Summit 2016 - A Healthier Future for Europe
From 09/11/2016 to 10/11/2016 (Brussels)

The event will bring together patient organisation representatives, healthcare professionals and industry leaders from across Europe to encourage dialogue and share best practice.

This year we will be focusing on the challenges and opportunities in developing a more outcomes-driven, sustainable approach to healthcare in Europe as well as optimal patient engagement throughout the lifecycle of a medicine.

Read more

Events Calendar

FT Global Pharmaceutical and Biotechnology Conference
From 15/11/2016 to 16/11/2016 (London, UK)

The FT Global Pharmaceutical and Biotechnology Conference, now in its 34th successful year, brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry and the business models and transformation strategies that will be needed to survive and thrive in an industry in flux.

Transformational shifts in healthcare markets herald challenges as well as opportunities ahead for the global life science industry. Considerations around value and outcomes of drug and other medical interventions are becoming a part of the fabric of the industry as health technology assessment and integrated care models gain traction in a growing number of markets.

For more information, click here.

Read more

Events Calendar

Certificate: European Healthcare Compliance Ethics & Regulation
From 14/11/2016 to 18/11/2016 (Barcelona)

The pharmaceutical, biotech and medical device industries are increasingly facing a more challenging regulatory and enforcement landscape throughout Europe. This intensive, multi-day educational and training certification in healthcare compliance addresses the myriad of legal, regulatory and compliance issues faced by pharmaceutical, biotech and medical device manufacturers working in healthcare compliance in Europe.

Read more

What we are reading

What we are reading

Using registries in real world evidence: paving the path for success
10 October 2016 (MAPPs Newsletter)

In this newsletter we look forward to the EMA Patient Registries Workshop to be held on 28 October 2016, at the EMA offices in London. The workshop is designed to bring together multiple stakeholders, including registry owners, industry, HTA representatives and regulators to discuss the challenges and barriers to collaboration and to identify specific solutions.

Read more

What we are reading

EPAD publishes breakthrough recommendations for the detection of early preclinical Alzheimer’s disease
13 October 2016 (EPAD)

We are thrilled to report on recent progress on the European Prevention of Alzheimer’s Dementia (EPAD) study. Just as we are nearing the point in time when the first follow-up visits are due, there have been two key papers that the EPAD consortium has published. The papers published this week summarise current assessment measures that are used for detecting cognitive decline – and highlight the lack of evidence-based guidelines for measuring cognitive change in a preclinical population where the cognitive decline is “silent” and has been occurring years before memory problems arise.

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail